Transforming the Field of Regenerative Medicine
Medical Energetics USA, Inc.’s DHC is a new and patented electromagnetic field therapy device. Superior benefits to patients are achieved due to its novel design which enables the production of a biologically efficient field shape. Remarkably, this technology has demonstrated a level of efficacy equivalent to mesenchymal stem cells (cells that can differentiate into a variety of cell types) however at a small fraction of the cost and without potential contraindications. It is unlike any other product on the market due to its inherent safety and remarkable effectiveness. While the multi-patented DHC is a very sophisticated technology, it is also extremely simple to use for a patient as the entire operational process has been automated by custom designed electronics and software. The patient or clinician turns the unit on and then selects the “run” button on the touch screen interface. The entire 45 minute therapy session is performed automatically without the need for a doctor or nurse to be present for the full session.
The long-term benefits of our unsolicited proposal are quantifiable in various ways. Medical Energetics USA, Inc.’s DHC Coil is a new and patented electromagnetic field therapy device that produces superior benefits not realized in other devices due to its novel design which results in the production of a biologically efficient field shape. After eight years of design and development this new technology has shown in studies:
- The ability to produce neurite outgrowth or formation of new neurons.
- Remarkable therapeutic effects in humans suffering from early stage Diabetic Neuropathy, with significant reductions in pain, inflammation and improvement in sensation.
- Accelerated wound healing as measured in a rabbit model, with levels of efficacy rivaling stem cells. The potential to prevent amputations is a real possibility.
- No contraindications reported.
- Incredibly safe due to low power levels utilized.
There is currently no effective, long term treatment for diabetic ulcerations which very often results in the amputation of the affected lower limb(s). The unique Double Helix Conductor device addresses this unmet clinical need and represents a revolutionary method for treating this condition. While the grant proposal is focused on taking the DHC technology to market for the treatment of Diabetic Neuropathy, one of the many exciting things about this opportunity is that this medical device potentially has application in other disorders such as Parkinson’s disease, Alzheimer’s disease, Multiple Sclerosis and ALS.